A Phase 1 of JNS002 (Doxorubicin HCl Liposome Injection) in Combination With Bortezomib for Japanese Patients With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2015
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 25 Jun 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.
- 26 Mar 2012 Actual patient number (3) added as reported by ClinicalTrials.gov.